플랫폼과 전략
논문 &학회발표
Home플랫폼과 전략논문 &학회발표
논문
| 과제 | 저널 | 발표년도 | 발표제목 | 링크정보 | 발표자료 |
|---|---|---|---|---|---|
| General | Vaccines | 2021/Q3 | Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies |  |
 |
| ADC (Nterm) | mAbs | 2021 | N-terminal selective conjugation method widens the therapeutic window of antibody–drug conjugates by improving tolerability and stability | |
|
| ABL503 | JITC | 2021 | Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade | |
|
| 4-1BB Platform | Science Advances | 2021 | B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+tumor-infiltrating lymphocytes | |
|
| ABL001 | BMB Reports | 2020 | Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer | |
|
| Int J Mol Sci | 2020 | ABL001, a bispecific antibody targeting VEGF and DLL4, with chemotherapy, synergistically inhibits tumor progression in xenograft models | |
|
|
| mAbs | 2016 | Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis | |
|
학회발표
| 과제 | 학회 | 발표제목 | 발표자료 |
|---|---|---|---|
| ABL001 | PEGS 2017 | Preclinical development of an anti-cancer bispecific antibody targeting VEGF and DLL4, ABL001 | |
| ASCO 2019 | Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointesinal (GI) cancer | |
|
| PEPTALK 2020 | Summary of phase 1a dose escalation clinical study data for dual angiogenic bispecific antibody targeting VEGF and DLL4 (ABL001/NOV1501/TR009) in patients with previously treated solid tumors | |
|
| ABL105 | ESMO | A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activation | |
| 4-1BB Platform | AACR 2020 | B7-H3-targeted 4-1BB activation potentiates CD8 T cell-dependent antitumor immunity without systemic toxicity | |
| AACR 2021 | A novel anti-CD137 antibody recognizing the membrane-proximal CD137 domain elicits potent anti-tumor T cell activity in a bispecific antibody format | |
|
| ABL503 | SITC | ABL503 (TJ-L14B), PD-L1×4-1BB bispecific antibody, induces superior anti-tumor activity by PD-L1-dependent 4-1BB activation with the increase of 4-1BB+CD8 + T cells in tumor microenvironment | |
| PEGS 2019 | The PD-L1 x 4-1BB Bispecific Antibody ABL503 Shows Potent Anti-Tumor Effect through Tumor-Directed T Cell Activation | |
|
| ABL111 | SITC | TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumordependent immune response without dose-limiting toxicity in preclinical studies | |
| AACR 2020 | Claudin 18.2 x 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activation | |
|
| ABL501 | AACR | ABL501 (PD-L1xLAG-3), a bispecific antibody promotes enhanced human T cell activation through targeting simultaneously two immune checkpoint inhibitors, LAG-3 and PD-L1 | |
| Grabody T | AACR | A novel anti-CD137 antibody recognizing the membrane-proximal CD137 domain elicits potent anti-tumor T cell activity in a bispecific antibody format | |
| ABL103 | AACR 2022 | A novel T-cell engaging bispecific antibody, exhibits potent in vitro and vivoantitumor activity and low toxicity via B7-H4 dependent 4-1BB activation in tumor microenvironment | |
| PEGS Europe | A novel T-cell engaging bispecific antibody, ABL103, shows potent anti-tumor effect via B7-H4 mediated 4-1BB activation in TME | |
|
| ABL602 | ASH | A novel asymmetrical anti-CLL-1×CD3 bispecific antibody, ABL602, induces potent CLL1-specific antitumor activity with minimized sensitization of pro-inflammatory cytokines | |